Arlindo Lucas Castelhano

This inventor holds 44 USPTO granted patents and 2 published patent applications and 3 EPO patents, primarily in Metalloproteinase Inhibitors. Top assignees: Osi Pharmaceuticals, Inc., Syntex (u.s.a.) Inc., Agouron Pharmaceuticals, Inc.. Active years: 1998-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Arlindo Lucas Castelhano. Retrieved from https://idiyas.com/inventor/arlindo-lucas-castelhano

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 44 (Patent Applications = 2)

% Patents Active = 59.1

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 3.9

ph-index = 13

Forward Citations = 441(Granted Patents)

Location History:

Pleasanton, CA (US) (2000)
Farmingdale, NY (US) (2008 - 2010)
New City, NY (US) (1998 - 2013)
New York, NY (US) (1999 - 2022)

Company Filing History:

25 out of 118

Osi Pharmaceuticals, Inc.

Agouron Pharmaceuticals, Inc.

Cadus Pharmaceutical Corp.

7. 5 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2024

Loading Chart...

Areas of Expertise:

Metalloproteinase Inhibitors

Adenosine A1 Receptor

Adenosine A3 Receptor

mTOR Inhibitors

Crystalline Forms

c-Kit Inhibitors

Cytochrome P450 Inhibitors

Peptidomimetics

Pharmaceutical Compositions

Synthesis Methods

Heterocycles

Glucokinase Activators

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12116359 - EBNA1 inhibitor crystalline forms, and methods of preparing and using same (2024-10-15),

2. 11242338 - EBNA1 inhibitor crystalline forms, and methods of preparing and using same (2022-02-08),

3. 8557814 - mTOR inhibitor salt forms (2013-10-15),

4. 7829717 - (Arylamidoaryl)squaramide compounds (2010-11-09),

5. 7767673 - N-substituted imidazopyridine c-Kit inhibitors (2010-08-03),

6. 7662844 - Naphthylene derivatives as cytochrome P450 inhibitors (2010-02-16),

7. 7645754 - [object Object] (2010-01-12),

8. 7598252 - Compounds specific to adenosine A, receptors and uses thereof (2009-10-06),

9. 7521448 - N-substituted benzimidazolyl c-Kit inhibitors (2009-04-21),

10. 7504407 - [object Object] (2009-03-17),

11. 7501407 - [object Object] (2009-03-10),

12. 7485658 - N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors (2009-02-03),

13. 7442709 - N3-substituted imidazopyridine c-Kit inhibitors (2008-10-28),

14. 7439256 - (Arylamidoaryl) cyanoguanidine compounds (2008-10-21),

15. 7429574 - 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use (2008-09-30),

Sure, I can help you with that. Let's start with the structure you provided for the article about inventor Arlindo Lucas Castelhano:

Title: Innovator Spotlight: Arlindo Lucas Castelhano - Pioneering Solutions for Health Challenges

Introduction: Arlindo Lucas Castelhano, a prolific inventor based in New City, NY, has made significant contributions to the field of medicine through his groundbreaking patents.

Latest Patents: Among his impressive portfolio of 43 patents are the EBNA1 inhibitor crystalline forms and methods for treating EBV infections, as well as mTOR inhibitor salt forms for combating various diseases.

Career Highlights: Arlindo Lucas Castelhano has wielded his expertise at leading pharmaceutical companies such as Osi Pharmaceuticals, Inc. and Syntex (USA) Inc., where he honed his skills in developing innovative medical solutions.

Collaborations: Throughout his career, Arlindo has collaborated with esteemed professionals such as Bryan McKibben and David James Witter, fostering a culture of innovation and excellence in the pharmaceutical industry.

Conclusion: Arlindo Lucas Castelhano's relentless pursuit of scientific advancement and commitment to improving global healthcare make him a true pioneer in the field of medical inventions, leaving a lasting impact on countless lives worldwide.

I hope you find this structure helpful for the article about Arlindo Lucas Castelhano. If you need any more assistance or information, feel free to ask!

Profile summary based on public USPTO records.